UAE: Julphar’s 2023 accumulated losses hit 30% of capital; revenues up

Mohamed Al-Sayaghi

The incurred accumulated losses represent 30% of the company’s paid-up capital

Staff Writer, Mubasher

March 18, 2024

PHOTO

Abu Dhabi – Gulf Pharmaceutical Industries (Julphar) registered accumulated losses valued at AED 346.70 million as of 31 December 2023.

The incurred accumulated losses represent 30% of the company’s paid-up capital, according to a bourse disclosure.

In the 12-month period that ended on 31 December 2023, the net losses attributable to the owners of Julphar enlarged to AED 99.10 million from AED 29.40 million.

Basic and diluted loss per share hit AED 8.60 last year, higher than AED 2.50 in 2022.

The revenues from contracts with customers rose year-on-year (YoY) to AED 1.63 billion in 2023 from 1.61 billion.

In the first nine months (9M) of 2023, Julphar turned to net losses worth AED 83.40 million, compared to net profits valued at AED 10.40 million in 9M-22.

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.